(Q39576482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401755%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401755%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

author name string

M Di Salvatore

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

C Bagalà

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

M Quirino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

A Cassano

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

A Astone

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

C Barone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

publication date

1 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21401755%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

volume

44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

page(s)

139-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

Zoledronic acid - a multiplicity of anti-cancer action

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Prevention and management of bone metastases in lung cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Anti-tumour activity of zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Survivin gene expression in early-stage non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Zoledronic acid is synergic with vinblastine to induce apoptosis in a multidrug resistance protein-1 dependent way: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Anti-angiogenic therapy: adapting strategies to overcome resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2184.2011.00745.X

Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21401755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21401755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21401755

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2184.2011.00745.X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6496192&resulttype=core&format=json

14 May 2020

1 reference